The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Springtime for psychopharmacology
Abstract
As we head into the (Northern Hemisphere) spring, the Journal publishes another set of papers which illustrate the robust health of the science of psychopharmacology. Once again, papers mostly focus on psychedelic drugs and related topics reflecting the zeitgeist (Young, 2022). de Wit et al. (2022) explore translational challenges and opportunities between clinical research and laboratory settings. Using 3,4-methylenedioxymethamphetamine (MDMA) as an example, the authors highlight the methodological differences in determining how drugs can elicit positive clinical outcomes and the psychological processes by which these occur. By dissecting the widely recognised concept of ‘set and setting’, the pertinent issues of expectancy effects, inter-individual subject characteristics and confounding influences of physical and social context are examined. The authors make practical recommendations, for example, the identification of standardised outcome measures that are appropriate for varied research settings. These suggestions should inform study design aimed at harmonising laboratory based and psychiatric research, in the pursuit of improved cognitive neuropsychological hypotheses in relation to clinical improvement. Schlag et al. (2022) review adverse effects associated with the classical psychedelics. They note minimal evidence for widely perceived risks such as neurotoxicity and abuse potential. While risks such as psychosis or self-harm may occur in individual cases, they can be…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Adverse effects of psychedelics: From anecdotes and misinformation to systematic science
Schlag, A. K., Aday, J., Salam, I., Neill, J. C., & Nutt, D. J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211069100 · Cited by 325
A narrative synthesis of research with 5-MeO-DMT
Ermakova, A. O., Dunbar, F., Rucker, J., & Johnson, M. W. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211050543 · Cited by 100
Uthaug, M. V., Davis, A. K., Haas, T. F., Davis, D. D., Dolan, S. B., Lancelotta, R., Timmermann, C., & Ramaekers, J. G. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211013583 · Cited by 77
Maples‐Keller, J. L., Norrholm, S. D., Burton, M. S., Reiff, C. M., Coghlan, C., Jovanović, T., Yasinski, C. W., Jarboe, K. S., Rakofsky, J. J., Rauch, S. A. M., et al. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211069124 · Cited by 62
Wolff, M., Mertens, L. J., Walter, M., Enge, S., & Evens, R. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211073758 · Cited by 58 · cited 1×
“Wolff et al. (2022) present The Acceptance/AvoidancePromoting Experiences Questionnaire (APEQ) and provide initial validation for the scale.”
MethodEffects of caffeine on vigilance and other performance tests in normal subjects
Fagan, D., Swift, C. G., & Tiplady, B. (1988) · Journal of Psychopharmacology · doi:10.1177/026988118800200104 · Cited by 55
Wießner, I., Falchi-Carvalho, M., Maia, L. O., Daldegan‐Bueno, D., Palhano-Fontes, F., Mason, N. L., Ramaekers, J. G., Gross, M. E., Schooler, J. W., Feilding, A., et al. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211069113 · Cited by 54
Agin-Liebes, G., Zeifman, R., Luoma, J. B., Garland, E. L., Campbell, W. K., & Weiss, B. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221080165 · Cited by 54 · cited 6×
“de Wit et al. (2022) explore translational challenges and opportunities between clinical research and laboratory settings. Using 3,4-methylenedioxymethamphetamine (MDMA) as an example, the authors highlight the methodological differences in determining how drugs can elicit positive clinical outcomes and the psychologi…”
BackgroundInfluentialDevelopment and validation of the Reward Deficiency Syndrome Questionnaire (RDSQ-29)
Kótyuk, E., Urbán, R., Hende, B., Richman, M. J., Mägi, A., Király, O., Barta, C., Griffiths, M. D., Potenza, M. N., Badgaiyan, R. D., et al. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211069102 · Cited by 37
Debunking the myth of ‘Blue Mondays’: No evidence of affect drop after taking clinical MDMA
Sessa, B., Aday, J. S., O’Brien, S., Curran, H. V., Measham, F. C., Higbed, L., & Nutt, D. J. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211055809 · Cited by 24
Metadata
- Authors
- Bird, C., & Young, A. H.
- Affiliations
- King's College London (GB)
- Corresponding author
- Young, Allan H
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2022-03
- Volume
- 36
- Issue
- 3
- Pages
- 249-251
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W4220968654
- Cited by
- 0
- References
- 14
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Psychology Research and Bibliometrics
- Social Sciences › Psychology › Clinical Psychology › Historical Psychiatry and Medical Practices
- MeSH terms
- Psychopharmacology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Springtime for psychopharmacology. https://app.cochat.ai/papers/10.1177/02698811221085764
- The paper
- Bird, C., & Young, A. H. (2022). Springtime for psychopharmacology. Journal of Psychopharmacology. https://doi.org/10.1177/02698811221085764
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.